Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Voronoi has developed a robust AI-powered drug discovery engine ("Voronomix") validated on millions of experimental data points. It focuses on kinase inhibitors and protein degraders targeting CNS diseases and cancers. The company has established global partnerships, filed numerous patents, and signed major licensing deals including a $324 million agreement with Brickell Biotech. Clinical results have not been published as most programs remain preclinical or at IND-enabling stage [6][10].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Voronoi Pictures.